TR-494 Anthraquinone
Target Organs and Levels of Evidence
NTP Technical Report Number 494
Produced from Chemtrack Database 05/14/04
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| ANTHRAQUINONE 84-65-1 |
02/17/04 | INTERMEDIATE IN MANUFACTURE OF DYES AND OTHER ORGANICS. ORGANIC INHIBITOR. CATALYST. ACCELERATOR IN NICKEL ELECTROPLATING. IMPROVING ADHESION AND HEAT STABILITY OF TIRE CORD. (NTP EXECUTIVE SUMMARY) | Dosed-Feed R: 0, 469, 938, 1875, OR 3750 PPM M: 0, 833, 2500, OR 7500 PPM | Battelle Columbus Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: SOME EVIDENCE | KIDNEY TUBULAR CELL: ADENOMA 1/50 3/50 9/50 5/50 3/50 | |||
| KIDNEY TRANSITIONAL CELL: PAPILLOMA 0/50 0/50 2/50 0/50 1/50 | ||||
| URINARY BLADDER: TRANSITIONAL EPITHELIAL PAPILLOMA 0/50 1/50 3/50 7/50 3/49 | ||||
| MAY HAVE BEEN RELATED: | LIVER: ADENOMA OR CARCINOMA 1/50 3/50 4/50 5/50 3/50 | |||
| NON-NEOPLASTIC LESIONS: | KIDNEY: HYALINE DROPLET ACCUMULATION; INCREASED SEVERITY OF NEPHROPATHY; PIGMENTATION; MEDULLA MINERALIZATION; TRANSITIONAL EPITHELIAL HYPERPLASIA | |||
| LIVER: CENTRILOBULAR HYPERTROPHY; CYSTIC DEGENERATION; INFLAMMATION; EOSINOPHILIC FOCUS; MIXED CELL FOCUS; CYTOPLASMIC VACUOLIZATION | ||||
| SPLEEN: CONGESTION; PIGMENTATION; HEMATOPOIETIC CELL PROLIFERATION | ||||
| BONE MARROW: HYPERPLASIA | ||||
| OTHER CONSIDERATIONS: | HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 25/50 2/50 1/50 5/50 7/50 | |||
| FR: CLEAR EVIDENCE | KIDNEY TUBULAR CELL: ADENOMA 0/50 4/50 9/50 7/50 12/49; ADENOMA OR CARCINOMA 0/50 6/50 9/50 8/50 14/49 | |||
| URINARY BLADDER: TRANSITIONAL EPITHELIAL PAPILLOMA OR CARCINOMA 0/49 0/49 0/49 1/50 2/49 | ||||
| LIVER: ADENOMA 0/50 2/50 6/50 4/50 3/50 | ||||
| NON-NEOPLASTIC LESIONS: | KIDNEY: HYALINE DROPLET ACCUMULATION; NEPHROPATHY; PIGMENTATION; MEDULLA MINERALIZATION; TUBULAR CELL HYPERPLASIA; TRANSITIONAL EPITHELIAL HYPERPLASIA | |||
| LIVER: CENTRILOBULAR HYPERTROPHY; CYSTIC DEGENERATION; INFLAMMATION; EOSINOPHILIC FOCUS; MIXED CELL FOCUS; ANGIECTASIS | ||||
| SPLEEN: CONGESTION; PIGMENTATION; HEMATOPOIETIC CELL PROLIFERATION | ||||
| BONE MARROW: HYPERPLASIA; ATROPHY | ||||
| OTHER CONSIDERATIONS: | HEMATOPOIETIC SYSTEM: MONONUCLEAR CELL LEUKEMIA 18/50 1/50 1/50 2/50 0/50 | |||
| MM: CLEAR EVIDENCE | LIVER: ADENOMA 21/50 32/50 38/50 41/49 OR CARCINOMA 8/50 13/50 17/50 21/49 OR HEPATOBLASTOMA 1/50 6/50 11/50 37/49 COMBINED 26/50 35/50 43/50 48/49 | |||
| MAY HAVE BEEN RELATED: | THYROID GLAND: FOLLICULAR CELL ADENOMA 0/50 0/50 2/49 2/46 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: CENTRILOBULAR HYPERTROPHY; FOCAL DEGENERATION; HEPATOCYTE ERYTHROPHAGOCYTOSIS; EOSINOPHILIC FOCUS; FOCAL NECROSIS | |||
| URINARY BLADDER: INTRACYTOPLASMIC INCLUSION BODY | ||||
| THYROID GLAND: FOLLICULAR CELL HYPERPLASIA | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
| KIDNEY: PIGMENTATION | ||||
| FM: CLEAR EVIDENCE | LIVER: ADENOMA 6/49 28/50 27/50 40/49 OR CARCINOMA 2/49 3/50 8/50 8/49 COMBINED 6/49 30/50 30/50 41/49 | |||
| MAY HAVE BEEN RELATED: | THYROID GLAND: FOLLICULAR CELL ADENOMA 1/45 1/48 2/48 2/48 OR CARCINOMA 0/45 0/48 0/48 2/48 COMBINED 1/45 1/48 2/48 4/48 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: CENTRILOBULAR HYPERTROPHY; FOCAL DEGENERATION; EOSINOPHILIC FOCUS | |||
| URINARY BLADDER: INTRACYTOPLASMIC INCLUSION BODY | ||||
| SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
